As previously reported, Craig-Hallum initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $109 price target The firm notes Apogee is a clean, well-capitalized immunology platform building Dupixent 2.0 with its long-acting IL-13 antibody APG777, initially targeting the $20B+ atopic dermatitis market. 52-week durability data in Q1 2026 and a high-exposure induction cohort in Q2 2026 could show best-in-class efficacy and convenience, setting up a path to front-line use and expansion into asthma, COPD, and EoE, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics initiated with a Buy at Craig-Hallum
- Apogee Therapeutics’ APG777 Study: A Potential Breakthrough in Atopic Dermatitis Treatment
- Apogee Therapeutics’ New Study on Atopic Dermatitis: What Investors Need to Know
- Apogee Therapeutics’ Promising Update on Long-term APG777 Study for Atopic Dermatitis
- Mizuho Securities Recommends Buy for Apogee Therapeutics Due to Promising APG777 Efficacy in Th2 Inflammatory Diseases